Tuesday, 26 January 2021
SAGE recommendations on the
Moderna mRNA-1273 vaccine against COVID-19
WHO’s Strategic Advisory Group of Experts (SAGE) on Immunization today issued interim recommendations for use of the Moderna mRNA-1273 vaccine against COVID-19.
See also:
-
The Moderna COVID-19 (mRNA-1273) vaccine: what you need to know
-
SAGE presenting its interim recommendations on the use of the Moderna COVID-19 (mRNA-1273) vaccine to the journalists accredited to the United Nations Office at Geneva (UNOG), webcast of the press conference, 26 January
-
SAGE extraordinary meeting held on 21 January
- Background document on mRNA-1273 vaccine (Moderna) against COVID-19 and the Background paper on Covid-19 disease and vaccines
About SAGE:
The Strategic Advisory Group of Experts (SAGE) on Immunization is charged with advising WHO on overall global policies and strategies, ranging from vaccines and technology, research and development, to delivery of immunization and its linkages with other health interventions.
A SAGE Working Group on COVID-19 Vaccines was established in June 2020 and consists of 26 experts who have been considering all aspects that would inform policy recommendations, including values, ethics, clinical trial data, and programmatic considerations.
SAGE has undertaken a 3-step process to provide guidance for overall COVID-19 vaccination programme strategy as well as vaccine-specific recommendations:
- Values Framework for Allocation and Prioritization of COVID-19 vaccination was issued in September 2020
- Prioritization Roadmap for Prioritizing Uses of COVID-19 Vaccines in the Context of Limited Supply was issued in October 2020
- on 5 January, SAGE provided its first product-specific interim recommendation for COVID-19 vaccine use for the Pfizer BioNTech BNT162b2 mRNA vaccine.
For more information, visit https://www.who.int/groups/strategic-advisory-group-of-experts-on-immunization/working-groups
Media contacts:
Kommentare
Kommentar veröffentlichen